Source: Investing.com ↗

Novartis DM1 drug fails late-stage trial, clouding development outlook

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

BTC/USDT

$66,723.67

-4.59%

USDC/USDT

$1.00

-0.01%

ETH/USDT

$1,890.19

-4.58%

SOL/USDT

$75.46

-8.17%

USD1/USDT

$0.9987

-0.04%